Background Episodic cluster headache is a disabling neurologic disorder that is
characterized by daily headache attacks that occur over periods of weeks or months …

Objective To report efficacy and safety of galcanezumab in adults with chronic cluster
headache. Background Galcanezumab is a humanized monoclonal antibody that binds to …

Cluster headache is characterised by attacks of excruciating unilateral headache or facial
pain lasting 15 min to 3 h and is seen as one of the most intense forms of pain. Cluster …

Importance Signaling molecule calcitonin gene-related peptide (CGRP) induces migraine
attacks and anti-CGRP medications abort and prevent migraine attacks. Whether CGRP …

Importance Migraine is a disabling neurological disease characterized by severe headache
attacks. Treatment options reduce migraine frequency for many patients, but adverse effects …

Background Galcanezumab, a humanized monoclonal antibody that selectively binds to the
calcitonin gene-related peptide, has demonstrated in previous Phase 2 and Phase 3 clinical …

Introduction Galcanezumab is a humanized monoclonal antibody binding calcitonin gene-
related peptide, used for migraine prevention. Methods A global, double-blind, 6-month …

Importance Galcanezumab (LY2951742), a monoclonal antibody against calcitonin gene-
related peptide (CGRP), is one of a novel class of new medicines for migraine prevention …

Abstract Background and Purpose Cluster headache is a relatively rare, disabling primary
headache disorder with a major impact on patients' quality of life. This work presents …

Objective To evaluate onset of effect of galcanezumab in patients with episodic migraine.
Background Galcanezumab is a monoclonal antibody that binds to calcitonin gene‐related …